hodgkin's lymphoma

Kite's Tecartus™ (Brexucabtagene Autoleucel) Authorized by Health Canada for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Canada NewsWire - 28 Oct 2021
Kite's Tecartus™ (Brexucabtagene Autoleucel) Authorized by Health Canada for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma ...

Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma

pnas.org - 12 Oct 2021
Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma ...

Football: Wales and Bournemouth midfielder David Brooks diagnosed with cancer

The Straits Times - 14 Oct 2021
Football: Wales and Bournemouth midfielder David Brooks diagnosed with cancer ...

Trends in Use of Anti-Infective Prophylaxis With Non-Hodgkin Lymphoma Treatment

Oncology Nurse Advisor - 30 Sep 2021
Trends in Use of Anti-Infective Prophylaxis With Non-Hodgkin Lymphoma Treatment ...

HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China

Yahoo Finance UK - 28 Oct 2021
HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China ...

Elevated Risks of NHL, Lung Cancer Increase Mortality in Recipients of Organ Transplant

AJMC.com Managed Markets Network - 09 Oct 2021
Elevated Risks of NHL, Lung Cancer Increase Mortality in Recipients of Organ Transplant ...

Budde Considers Multiple Regimens for a Patient With DLBCL

Targeted Oncology - 13 Oct 2021
Budde Considers Multiple Regimens for a Patient With DLBCL ...

Hodgkin's Lymphoma vs. Non-Hodgkin's Lymphoma: Differences & More

Healthline - 20 Aug 2021
Hodgkin's Lymphoma vs. Non-Hodgkin's Lymphoma: Differences & More ...

CBMG bags $120M in its first financing since going private, funds to benefit CAR T candidates

BioWorld Online - 30 Sep 2021
CBMG bags $120M in its first financing since going private, funds to benefit CAR T candidates ...

Kyowa Kirin International: New Real World Evidence Underlines Benefits of POTELIGEO® (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients

Business Wire - 14 Oct 2021
Kyowa Kirin International: New Real World Evidence Underlines Benefits of POTELIGEO® (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients ...

"Big Boom" Radiation Treatment (RT) of 4 Gy Single Fraction: Is It an Acceptable Alternative to "Boom Boom" Radiation Treatment 2 Gyx2 Fractions for Non-Hodgkin Lymphomas (NHL)?

DocWire News - 27 Oct 2021
"Big Boom" Radiation Treatment (RT) of 4 Gy Single Fraction: Is It an Acceptable Alternative to "Boom Boom" Radiation Treatment 2 Gyx2 Fractions for Non-Hodgkin Lymphomas (NHL)? ...

From patient to entrepreneur: Julia Saulino launched a nonprofit to help cancer patients - Boston Business Journal

Boston Business Journal - 28 Oct 2021
From patient to entrepreneur: Julia Saulino launched a nonprofit to help cancer patients - Boston Business Journal ...

Survival Rates for Non-Hodgkin's Lymphoma

Healthline - 21 Sep 2021
Survival Rates for Non-Hodgkin's Lymphoma ...

Aptose (APTO) falls 2.39% to Close at $2.04 on October 27

Equities.com - 28 Oct 2021
Aptose (APTO) falls 2.39% to Close at $2.04 on October 27 ...

The impact of the COVID‐19 pandemic on African American cancer survivors

Wiley - 28 Oct 2021
The impact of the COVID‐19 pandemic on African American cancer survivors ...

Benzene exposure and non-Hodgkin lymphoma: a systematic review and meta-analysis of human studies

The Lancet - 24 Aug 2021
Benzene exposure and non-Hodgkin lymphoma: a systematic review and meta-analysis of human studies ...

Burkitt Lymphoma: Overview and More - Cancer

Verywell Health - 30 Aug 2021
Burkitt Lymphoma: Overview and More - Cancer ...

European Medicines Agency Validates Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma

Business Wire - 01 Oct 2021
European Medicines Agency Validates Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma ...

New C-CAR039 Therapy Is Safe and Effective in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Hematology Advisor - 07 Jun 2021
New C-CAR039 Therapy Is Safe and Effective in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma ...